| The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations |
42 |
| Acetaminophen Hepatotoxicity |
26 |
| NASH in Lean Individuals |
23 |
| Endoplasmic Reticulum Stress in Metabolic Liver Diseases and Hepatic Fibrosis |
20 |
| Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets |
19 |
| Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy |
18 |
| Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures |
14 |
| Nonalcoholic Fatty Liver Disease in Children |
13 |
| Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies |
13 |
| Noncoding RNA in Cholangiocarcinoma |
11 |
| Genetics of Nonalcoholic Fatty Liver Disease: From Pathogenesis to Therapeutics |
11 |
| Current Knowledge of Occult Hepatitis B Infection and Clinical Implications |
10 |
| ABCB4 Gene Aberrations in Human Liver Disease: An Evolving Spectrum |
10 |
| TGF-beta as Multifaceted Orchestrator in HCC Progression: Signaling, EMT, Immune Microenvironment, and Novel Therapeutic Perspectives |
10 |
| Prevention and Management of Bleeding Risk Related to Invasive Procedures in Cirrhosis |
10 |
| Hepatic Dendritic Cells, the Tolerogenic Liver Environment, and Liver Disease |
10 |
| The Receptor Interacting Protein Kinases in the Liver |
9 |
| Pyogenic Liver Abscess of Biliary Origin: The Existing Problems and Their Strategies |
8 |
| Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis-Associated Portal Vein Thrombosis |
7 |
| Liver Toxicity with Cancer Checkpoint Inhibitor Therapy |
7 |
| Effects of Antibiotic Therapy in Primary Sclerosing Cholangitis with and without Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis |
7 |
| Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms |
6 |
| Extracellular Vesicles in Liver Diseases: Diagnostic, Prognostic, and Therapeutic Application |
6 |
| Child-Pugh Classification: Time to Abandon? |
6 |
| Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma |
6 |
| Mucosal-Associated Invariant T Cells in Chronic Inflammatory Liver Disease |
5 |
| Concept of Viral Inhibitors via NTCP |
5 |
| Potential Mechanisms Underlying the Role of Coffee in Liver Health |
5 |
| Renal Function in Cirrhosis: A Critical Review of Available Tools |
5 |
| Management of HCV-Related Liver Disease in Hemophilia and Thalassemia |
5 |
| Alpha-fetoprotein for Diagnosis, Prognosis, and Transplant Selection |
5 |
| Unfolded Protein Response Sensors in Hepatic Lipid Metabolism and Nonalcoholic Fatty Liver Disease |
5 |
| Role of TGR5 (GPBAR1) in Liver Disease |
5 |
| Liver Transplantation for Neuroendocrine Tumors: What Have We Learned? |
5 |
| Regulation of Hepatic Inflammation via Macrophage Cell Death |
5 |
| Magnetic Resonance Imaging in Primary Sclerosing Cholangitis-Current State and Future Directions |
5 |
| A Critical Review of MELD as a Reliable Tool for Transplant Prioritization |
5 |
| Novel Drivers of the Inflammatory Response in Liver Injury and Fibrosis |
5 |
| Contributions of Fibroblasts, Extracellular Matrix, Stiffness, and Mechanosensing to Hepatocarcinogenesis |
4 |
| Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9 |
4 |
| Macrophages as a Cell-Based Therapy for Liver Disease |
4 |
| Hyperferritinemia in Nonalcoholic Fatty Liver Disease: Iron Accumulation or Inflammation? |
4 |
| Competing Endogenous RNAs in Hepatocellular Carcinoma-The Pinnacle of Rivalry |
4 |
| Circulating Tumor DNA and Hepatocellular Carcinoma |
4 |
| Hepatic Damage by Natural Remedies |
4 |
| Does Transjugular Intrahepatic Portosystemic Shunt Stent Differentially Improve Survival in a Subset of Cirrhotic Patients? |
4 |
| Organ Preservation in Liver Transplantation |
4 |
| Can Elastography Differentiate Isolated Fatty Liver from Nonalcoholic Steatohepatitis? |
3 |
| Genetic and Epigenetic Heterogeneity in Normal Liver Homeostasis and Its Implications for Liver Disease and Hepatocellular Cancer |
3 |
| Bacterial Infections in Acute-on-Chronic Liver Failure |
3 |
